Ibrutinib—A New Standard Treatment for Mantle Cell Lymphoma?

In The Lancet, Dr. Peter Martin commented on the results of a recently completed phase 3 trial in Europe that compared ibrutinib to temsirolimus among patients with mantle cell lymphoma. He writes that the results of the study clearly establish, “…ibrutinib as a new standard for treatment of relapsed mantle cell lymphoma.” Dr. Martin’s full comments on the topic can be found in the attached PDF below:

Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?

A full listing of currently available clinical trials for mantle cell lymphoma can be found on the Joint Clinical Trials website.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s